Reta is an investigational medication being studied for obesity, weight management, and metabolic health. It is sometimes referred to as a “triple agonist” because it activates three hormone receptors: GLP-1, GIP, and glucagon.
Research interest includes:
Weight reduction and weight management
Appetite and food-intake regulation
Blood-sugar and metabolic pathways
Energy expenditure
Cardiometabolic health
Clinical trials have shown substantial weight-loss effects, but research is still ongoing.
